Company intelligence / Profile preview

Enara Bio

Oxford/London*, United Kingdomenarabio.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Enara Bio has not yet reported clinical results but has received significant external validation through partnerships and licensing deals. The company’s pipeline includes first-in-class TCR-based therapies targeting novel Dark Antigens®, with the most advanced programs approaching clinical entry. Boehringer Ingelheim has licensed multiple antigens for off-the-shelf therapeutic vaccines in NSCLC.

Therapeutic areas: Oncology
Modalities: TCR-based immunotherapiesbispecific T-cell engagers
Industry: Biotech

Drug pipeline

2 assets

ENA101

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Boehringer Ingelheim (antigen licensing for NSCLC vaccines)Francis Crick Institute (academic collaboration)

Beyond the preview

Go deeper on Enara Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enara Bio.

Explore the full profile